Abstract: The present disclosure relates to novel compounds that are activators of the cystathionine-gamma-lyase enzyme (CSE). The disclosure also relates to methods for preparing the compounds, methods of treatment and/or prevention and to pharmaceutical compositions comprising such compounds.

Abstract: The present invention relates to a compound of formula (I), pharmaceutically acceptable salts thereof as well as pharmaceutical compositions, for use in a method of topical treatment of a skin disease or skin disorder of a mammal, wherein said method comprises topical administration of said compound to said mammal, Formula (I) wherein R1 is selected from carbocyclyl or heterocyclyl, each independently optionally substituted with C1-C4alkyl, halogen, oxo, CF3, OR4, NR5R6, C6H5, C6H5 substituted with halogen, C1-C3alkyl, OR4, NR5R6, wherein R4, R5, R6 are independently at each occurrence H, C1-C3alkyl; R2 is selected from C5-C12alkyl, C4-C10alkoxy, C1-C3 alkylene-cycloalkyl, C1-C3alkylene-aryl, C1-C3alkylene-heteroaryl, wherein said alkyl, cycloalkyl, aryl and heteroaryl are each independently optionally substituted with one or more, typically and preferably one or two, substituents selected from C1-C2 alkyl, C1-C2 haloalkyl, halogen, C1-C2 alkoxy; R3 is (Ia), wherein R7, R8, R9 and R10 are independently at eac

Abstract: The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.

Abstract: The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.

Abstract: According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.

Abstract: According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.